While the efficacy outcome falls short of the 95 percent preliminary result recently reported by both Moderna and Pfizer/BioNTech, the result is still very promising. At around $3 to $4 per dose, the AstraZeneca-Oxford shot is also the cheapest of the three options and should be easier to distribute globally (since it can be stored in regular refrigerators). That’s why lower-income countries around the world have been pre-purchasing access.
AstraZeneca said the company has the capacity to supply 3 billion doses of the vaccine in 2021.
The AstraZeneca-Oxford vaccine, however, can be stored in a normal refrigerator for at least six months.
That’s why the AstraZeneca-Oxford vaccine has become the leading contender lower-income countries are relying on to end their epidemics. According to Bloomberg, the shot “accounts for more than 40% of the supplies” going to low- and middle-income countries.
“[T]he vaccine’s simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available supplying hundreds of millions of doses on approval,” said Pascal Soriot, CEO of AstraZeneca, in a statement.
Source: AstraZeneca-Oxford Covid-19 vaccine: Why it’s different – Vox
Source:

You must be logged in to post a comment.